BioPharma Resources

Drug Trial Radar · NCT03090659

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

Last checked: Nov 19, 2026Latest source record: Jun 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 2, 2015

Primary completion

Dec 31, 2023

Study completion Dec 31, 2023

Sponsor

Lead sponsor
Nanjing Legend Biotech Co.Industry
Sponsor type
Industry
Collaborators
Second Affiliated Hospital of Xi'an Jiaotong University; Ruijin Hospital; Jiangsu Provincial People's Hospital; Shanghai Changzheng Hospital
First posted
Mar 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of LCAR-B38M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).

Conditions

  • Refractory or Relapsed Multiple Myeloma

Interventions

  • LCAR-B38M CAR-T cell injectionBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of treatment related adverse events as assessed by CTCAE v4.0Time frame: Day 1-30 days after injection

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.